PT  - JOURNAL ARTICLE
AU  - Nitasha Singh
AU  - Val Lewington
TI  - Molecular radiotheragnostics in thyroid disease
AID  - 10.7861/clinmedicine.17-5-453
DP  - 2017 Oct 01
TA  - Clinical Medicine
PG  - 453--457
VI  - 17
IP  - 5
4099  - http://www.rcpjournals.org/content/17/5/453.short
4100  - http://www.rcpjournals.org/content/17/5/453.full
SO  - Clin Med2017 Oct 01; 17
AB  - Molecular radiotheragnostics directly links nuclear medicine diagnostic imaging to therapy. The imaging study is used to detect a specific molecular target associated with a disease process. A radiotherapeutic molecule with a similar biodistribution to the diagnostic agent can then be used to deliver targeted therapy.Molecular radiotheragnostics have been applied to manage both benign and malignant thyroid disease since the 1940s. The specific molecular pathway targeted is the sodium/iodide symporter (NIS) located on the basolateral membrane of the thyroid follicular cell. Radiolabelling of iodide or a similar ion allows targeting of the NIS system with radiopharmaceuticals for imaging (123I-radioiodine and 99mTc-pertechnetate) and treatment (131I-radioiodine) by virtue of their gamma ray and beta-particle emissions, respectively.Scintigraphic imaging directly guides 131I-radioiodine treatment planning to maximise therapeutic benefit while minimising adverse reactions, in a personalised medicine approach.